---
title: "FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288365897.md"
description: "FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News"
datetime: "2026-06-01T21:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288365897.md)
  - [en](https://longbridge.com/en/news/288365897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288365897.md)
---

# FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility | RHHBY Stock News](https://longbridge.com/en/news/296263320.md)
- [Roche (OTCMKTS:RHHBY) Stock Price Passes Above 50-Day Moving Average   - Time to Sell?](https://longbridge.com/en/news/296314310.md)
- [Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295850563.md)
- [Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billion](https://longbridge.com/en/news/293380197.md)
- [Pfizer Inc. $PFE Shares Bought by Farther Finance Advisors LLC](https://longbridge.com/en/news/296071335.md)